Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy

被引：0
|
作者：
Wang, Ruibin
Ding, Zhijie
Lu, Xiaoxiao
Mavani, Heena
He, Jinghua
Qureshi, Zaina P.
Pinilla-Ibarz, Javier
机构：
[1] Janssen Sci Affairs, LLC, Titusville, NJ USA
[2] Janssen Sci Affairs, LLC, Horsham, PA USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19509
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 : S170 - S170
  • [2] Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S330 - S330
  • [3] Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina
    He, Jinghua
    Qian, Yi
    Huang, Qing
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Jacobs, Ryan
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S280 - S281
  • [4] Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
    Lu, Xiaoxiao
    Emond, Bruno
    Morrison, Laura
    Kinkead, Frederic
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Khan, Wasiulla
    Wu, Linda H.
    Qureshi, Zaina P.
    Jacobs, Ryan
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 2073 - 2084
  • [5] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Qing Huang
    Kathleen L. Deering
    Qing Harshaw
    Lori A. Leslie
    [J]. Advances in Therapy, 2022, 39 : 3292 - 3307
  • [6] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Huang, Qing
    Deering, Kathleen L.
    Harshaw, Qing
    Leslie, Lori A.
    [J]. ADVANCES IN THERAPY, 2022, 39 (07) : 3292 - 3307
  • [7] Real-world Comparison of Adherence Between Patients with Chronic Lymphocytic Leukemia Treated with Single-agent Ibrutinib or Acalabrutinib In First Line
    Lu Xiaoxiao
    Bruno, Emond
    Laura, Morrison
    Frederic, Kinkead Frederic
    Patrick, Lefebvre
    Helene, Marie-Lafeuille
    Wasiulla, Khan
    Wu Linda
    Zaina, P. Qureshi Zaina P.
    Ryan, Jacobs
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S26 - S26
  • [8] Real-World Outcomes of Patients Treated with Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Systematic Review and Meta-Analysis
    Cheung, Matthew C.
    Amitai, Irina
    [J]. BLOOD, 2020, 136
  • [9] Retrospective Analysis of Real-World Outcomes of Chronic/ Small Lymphocytic Leukemia (CLL/SLL) Patients Treated With First-Line Ibrutinib Versus Chemoimmunotherapy (CIT)
    Ran, Tao
    He, Jinghua
    Wu, Linda
    Panjabi, Sumeet
    Lu, Xiaoxiao
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S275 - S276
  • [10] REAL-WORLD ECONOMIC OUTCOMES OF FIRST-LINE (1L) IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
    Challagulla, S.
    Lee, P.
    Kistler, K.
    Douyon, L.
    Lai, D.
    Iyengar, R.
    [J]. VALUE IN HEALTH, 2021, 24 : S38 - S38
12345